Home > Prostate Cancer Research > Research News > AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy
Research News
AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy
Astra Zeneca announced today that their MedImmune division has partnered with a Portland Biotec startup, AgonOx, to develop OX40 agonist monoclonal antibody. PCF-funded researchers, Drs. William Redmond and Brendan Curti, have been fundamental in the early research.
Read the Press Release Here.
Read about Dr. Redmond's Young Investigator Award and Dr. Curti's Creativity Award Here.
Print |
Stay Informed
Sign up to receive our monthly newsletters.
Research Summaries
News from PCF's annual meeting of prostate cancer researchers.
PCF Guides
Report to the Nation on Prostate Cancer: A Guide for Men and Their Families
Nutrition, Exercise and Prostate Cancer